Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction

Masanobu Ishii, MD; Koichi Kaikita, MD, PhD; Koji Sato, MD, PhD; Daisuke Sueta, MD, PhD; Koichiro Fujisue, MD, PhD; Yuichiro Arima, MD, PhD; Yu Oimatsu, MD; Tatsuro Mitsuse, MD; Yoshiro Onoue, MD, PhD; Satoshi Araki, MD, PhD; Megumi Yamamuro, MD, PhD; Taishi Nakamura, MD, PhD; Yasuhiro Izumiya, MD, PhD; Eiichiro Yamamoto, MD, PhD; Sunao Kojima, MD, PhD; Shokei Kim-Mitsuyama, MD, PhD; Hisao Ogawa, MD, PhD; Kenichi Tsujita, MD, PhD

doi:10.1016/j.jacbts.2017.08.001

JACC: Basic to Translational Science (Dec 2017)

Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction

Masanobu Ishii, MD,
Koichi Kaikita, MD, PhD,
Koji Sato, MD, PhD,
Daisuke Sueta, MD, PhD,
Koichiro Fujisue, MD, PhD,
Yuichiro Arima, MD, PhD,
Yu Oimatsu, MD,
Tatsuro Mitsuse, MD,
Yoshiro Onoue, MD, PhD,
Satoshi Araki, MD, PhD,
Megumi Yamamuro, MD, PhD,
Taishi Nakamura, MD, PhD,
Yasuhiro Izumiya, MD, PhD,
Eiichiro Yamamoto, MD, PhD,
Sunao Kojima, MD, PhD,
Shokei Kim-Mitsuyama, MD, PhD,
Hisao Ogawa, MD, PhD,
Kenichi Tsujita, MD, PhD

Affiliations

Masanobu Ishii, MD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Koichi Kaikita, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Koji Sato, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Daisuke Sueta, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Koichiro Fujisue, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Yuichiro Arima, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Yu Oimatsu, MD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Tatsuro Mitsuse, MD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Yoshiro Onoue, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Satoshi Araki, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Megumi Yamamuro, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Taishi Nakamura, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Yasuhiro Izumiya, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Eiichiro Yamamoto, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Sunao Kojima, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
Shokei Kim-Mitsuyama, MD, PhD: Department of Pharmacology and Molecular Therapeutics, Kumamoto University, Kumamoto, Japan
Hisao Ogawa, MD, PhD: Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
Kenichi Tsujita, MD, PhD: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

DOI: https://doi.org/10.1016/j.jacbts.2017.08.001
Journal volume & issue: Vol. 2, no. 6
pp. 655 – 668

Abstract

Read online

LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to the suppression of pro-inflammatory cytokines, matrix metalloproteinase-9 activity and aldosterone production, and enhancement of natriuretic peptides in mice. These findings suggest the mechanistic insight of cardioprotective effects of LCZ696 against acute MI, resulting in the belief that LCZ696 might be useful clinically to improve survival after acute MI.

Published in JACC: Basic to Translational Science

ISSN: 2452-302X (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.journals.elsevier.com/jacc-basic-to-translational-science/

About the journal

Abstract

Keywords